文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

靶向BCMA的mRNA CAR T细胞疗法治疗重症肌无力:一项随机、双盲、安慰剂对照2b期试验

BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.
PubMed 文献 · Nat Med · 2026-01-09

这项2b期随机双盲安慰剂对照试验评估了Descartes-08(一种自体BCMA靶向mRNA CAR T细胞疗法)治疗全身型重症肌无力(gMG)。26例患者随机接受每周一次静脉输注Descartes-08(n=15)或安慰剂(n=11)共6周。第3个月时,Descartes-08组MGC评分≥5分改善的比例显著高于安慰剂组(66.7% vs 27.3%,P=0.0472)。Descartes-08总体安全且耐受性良好。

要点

  • 第3个月MGC评分≥5分改善比例:Descartes-08组66.7%(10/15)vs 安慰剂组27.3%(3/11),P=0.0472。
  • 抗乙酰胆碱受体抗体阳性亚组中,Descartes-08组63.6%(7/11)vs 安慰剂组12.5%(1/8),P=0.0258。
  • Descartes-08组第4个月MGC、MG-ADL和QMG评分较基线平均变化分别为-7.1、-5.5和-4.8。

核心结论

  • 单疗程六次每周一次输注Descartes-08耐受性良好,并在gMG患者中产生持续的临床有意义应答。

研究设计与样本

  • 2b期随机、对照、双盲试验,纳入26例全身型重症肌无力(gMG)患者,随机接受每周一次静脉输注Descartes-08(n=15)或安慰剂(n=11)共6周。

主要发现

  • 第3个月MGC评分≥5分改善比例:Descartes-08组66.7%(n=10/15)vs 安慰剂组27.3%(n=3/11),P=0.0472。
  • 抗乙酰胆碱受体抗体阳性亚组第3个月MGC评分≥5分改善比例:Descartes-08组63.6%(n=7/11)vs 安慰剂组12.5%(n=1/8),P=0.0258。
  • Descartes-08组第4个月MGC、MG-ADL和QMG评分较基线平均变化分别为-7.1、-5.5和-4.8。
  • Descartes-08组83.0%的患者在第12个月达到持续且临床有意义的应答。
  • Descartes-08组33.0%的患者在第6个月达到最低症状表达(MSE)(MG-ADL评分≤1),并持续至第12个月。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Myasthenia gravis (MG) is driven by the secretion of autoantibodies from pathogenic B cell maturation antigen (BCMA)-expressing plasma cells. In this phase 2b randomized, controlled, double-blind trial, we evaluated Descartes-08, an autologous BCMA-directed mRNA chimeric antigen receptor T cell therapy, in patients with generalized MG (gMG). Patients (n = 26) were randomly allocated to receive once-weekly intravenous infusions of Descartes-08 (n = 15) or placebo (n = 11) over 6 weeks. The primary endpoint was a ≥5-point improvement in the MG Composite (MGC) score at month 3. Secondary endpoints included the mean change from baseline in MGC, MG Activities of Daily Living (MG-ADL) and Quantitative MG (QMG) scores by month 12. At month 3, the proportion of patients achieving a ≥5-point improvement in the MGC score was significantly higher for those treated with Descartes-08 compared to placebo in the overall population (66.7% (n = 10/15) versus 27.3% (n = 3/11), P = 0.0472) and in a subpopulation of those positive for autoantibodies to the acetylcholine receptor (63.6% (n = 7/11) versus 12.5% (n = 1/8), P = 0.0258). For patients treated with Descartes-08, the changes from baseline in mean MGC, MG-ADL and QMG scores at month 4 were -7.1, -5.5 and -4.8, respectively, with 83.0% of patients achieving a sustained and clinically meaningful response at month 12. Notably, 33.0% of patients achieved minimum symptom expression (MSE) (MG-ADL score ≤1) by month 6, which was sustained through month 12. Among biologic-naive patients, 55.60% achieved MSE by month 6, which was maintained through month 12 without additional treatment. Descartes-08 was generally safe and well tolerated. Infusion-related reactions were the most common adverse events reported (Descartes-08, 80.0% (n = 16/20); placebo, 56.3% (n = 9/16)). In summary, a single course of six once-weekly infusions of Descartes-08 was well tolerated and resulted in sustained clinically meaningful responses among patients with gMG. ClinicalTrials.gov identifier: NCT04146051 .

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Vu T, Durmus H, Rivner M, et al. BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 2026. PMID: 41514038. doi:10.1038/s41591-025-04171-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。